One-carbon therapeutics
Our teams
Read more about who we are.
Meny
Read more about who we are.
Ana has 17 years of experience in oncology research from both academia and industry. She received Ph.D. in cellular biology and health economics education from the Medical Faculty, University of Oslo. She conducted her academic research on solid tumor therapies at the Department of Pathology, Oslo University Hospital, and The Wistar Institute, Philadelphia US.
She recently held a translational research director position at Oncopeptides AB where she was responsible for developing and implementing translational research strategies in the early and late-stage clinical trial pipeline. Before joining Oncopeptides AB, she was also the principal investigator for in vivo pharmacology at Medivir AS.
Thomas has >15 years experience as full professor, researching DNA damage response (DDR) and DNA repair at University of Oxford, Univ of Sheffield, Stockholm University and now Karolinska Institutet. He currently heads a large multidisciplinary translational research group at SciLifeLab, Helleday Laboratory, focusing on understanding DDR biology and translating the findings into novel anti-cancer treatments concepts and drugs. The group was first to demonstrate the synthetic lethality concept for treating cancer by showing homologous recombination defective cancers (e.g., BRCA) were sensitive to PARP inhibitors. Professor Helleday has been awarded numerous eminent international grants and awards in recognition of his research accomplishments including the Eppendorf-Nature Young European Investigator Award (2005) and ERC advanced grants (2010 and 2016).
Petra has a MSc degree in Biology from Uppsala University and has a lot of expertise in the DDR area and has been involved not only in the MTHFD2 project for many years but also been leading development of novel targets.
Martin has 30 years of experience as a medicinal chemist and project leader in both industry and academic settings, with experience from Oxford Diversity PLC, Pharmacia AB, Biovitrum AB, Orexo AB and Oxcia AB. He built-up a medicinal chemistry team in the Helleday Lab, which he leads since 2010, based within SciLifeLab, Karolinska Institutet. He has been closely involved in chemical manufacturing and control and pharmaceutical development and in the discovery of several small molecule inhibitors. He received a PhD in chemistry from the University of Edinburgh in 1989.
Magnus is a physician and scientist, who early in his career successfully started a medical technology company (Aerocrine) and sold it, joined Sanofi and subsequently has been a Partner at three life science Venture Capital firms: HealthCap in Stockholm, The Column Group in San Francisco, and currently at Eir Ventures in Stockholm. He has had a role in dozens of investments and exits, and has been actively involved in a number of successful pharma spin-outs. Lately, Magnus has been an independent Chairman/Board member in several private and public companies in the Nordics and the US, and worked on a weekly basis as a clinician. He has experience from the academic incubator space as CEO at Karolinska Institutet Holding.
Jan has 39 years of legal experience in the pharmaceutical industry, mostly at AstraZeneca, serving as Legal Counsel, Senior Counsel, Vice President, Strategy, Intellectual Property and Assistant General Counsel. He has provided global legal support in all areas of business including corporate functions, R&D, operations, and business development. Jan Zetterberg is elected Chairman of the Board of Oxcia AB and ExThera AB. He is also Board member of Elicera Therapeutics AB and Thomas Helleday’s Foundation for medical research. Jan Zetterberg obtained his L.L.B in Law and economics from Uppsala University in 1975.
Thomas has >15 years experience as full professor, researching DNA damage response (DDR) and DNA repair at University of Oxford, Univ of Sheffield, Stockholm University and now Karolinska Institutet. He currently heads a large multidisciplinary translational research group at SciLifeLab, Helleday Laboratory, focusing on understanding DDR biology and translating the findings into novel anti-cancer treatments concepts and drugs. The group was first to demonstrate the synthetic lethality concept for treating cancer by showing homologous recombination defective cancers (e.g., BRCA) were sensitive to PARP inhibitors. Professor Helleday has been awarded numerous eminent international grants and awards in recognition of his research accomplishments including the Eppendorf-Nature Young European Investigator Award (2005) and ERC advanced grants (2010 and 2016).
Alexander has a PhD in cell and molecular biology and an MBA in Management. He started off his corporate life science career in the global pharma industry at Novartis and Bayer, where he held several strategic R&D positions. He later moved to Alecta as healthcare Equity Analyst, gaining institutional experience in identifying and evaluating larger life science investments. He is currently Principal at Eir Ventures.
Martin is a medicinal chemist with 20 years of experience from Biovitrum, AstraZeneca, Biochromix and Karolinska Institutet. He joined the Helleday lab in 2013 and has a strong interest and expertise in drug discovery and metabolism. Martin led the medchem lead optimisation work in the MTHFD2 project, which involved >10 medicinal chemists, and has also taken responsibility for biological strategies.
Evert joined the Helleday laboratory in 2013 as a computational chemist and project leader, after having worked for 15 years in the pharmaceutical industry (Pharmacopeia Inc, Pharmacia & Upjohn, Biovitrum and Beactica). He has a strong interest and expertise in target discovery, fragment- and structure-based drug discovery, computational medicinal chemistry and cheminformatics. Evert has been instrumental to initiating and developing the MTHFD2 project. He holds a Masters degree in pharmacy and an PhD in medicinal chemistry from the University of Groningen, the Netherlands.
Roger has >10 years of experience leading clinical oncological development in an industrial setting and is currently the Chief Medical Officer of Isofol Medical AB, conducting a global phase III trial with Arfolitixorin ([6R]-5,10-Methylenetetrahydrofolate) that is the substrate of MTHFD2 (target of one-carbon therapeutics’ lead program). Prior to Isofol Medical AB, he has served as Vice President of Clinical Development at Aprea Therapeutics in Boston/Stockholm and International Clinical Project Director at Servier in Suresnes, France. He has extensive experience as an oncologist as well as an advisor to several biopharma companies, including Eli Lilly, AstraZeneca and Merck Serono. Roger holds a medical degree and a doctorate in experimental oncology from the Karolinska Institutet in Sweden, and he completed his residency in oncology at the Karolinska University Hospital.
Juha is a prize-winning entrepreneur who has pioneered AI-driven imaging to predict responses to cancer treatments by ex vivo high-throughput screening using patient-derived tumour biopsies. He is the founder and CEO of the company Misvik Biology and lecturer at University of Sheffield, integrating ex vivo screening with the cancer clinic. Dr Rantala has previous experience in pioneering ex vivo screening as assistant professor from the Knight Cancer Institute, in Oregon. He received his PhD from University of Turku.
Sarah is a Professor of Medical Oncology in the University of Sheffield and Honorary Consultant in Medical Oncology at Weston Park Cancer Centre, Sheffield. Professor Danson qualified in 1996 from the University of Nottingham and was a Specialist Registrar and Cancer Research UK Clinical Research Fellow in Pharmacology at the Christie Hospital, Manchester before moving to Sheffield in November 2006. Since 2019 she is chair of the Adult ECMC Network in the UK and NIHR National Specialty Lead for Cancer: Early Phase.
